~~<i id='841A1E73F6'><strike id='841A1E73F6'><tt id='841A1E73F6'><pre id='841A1E73F6'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：hotspot 2025-09-29 13:46:59 Page View：83

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Telehealth startups turn to complex chronic diseases
Next article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

knowledge

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Why some fertility treatments produce more boy babies

APStockBabiesbornbyinvitrofertilization—whenawoman’seggisfertilizedoutsideofherbodyandthenimplantedb

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

Google says AlphaFold 3 can map a vast universe of biomolecules

DeepMindGoogleonWednesdayunveiledanartificialintelligencetoolcapableofpredictingthestructureandinter